Unlocking the next generation of imaging agents for precision diagnosis.

Finding cancer early changes everything. We help doctors see it sooner and with more precision.

Our mission
Building the next-generation platform for precision cancer diagnostics and therapeutics.
What we do

One platform. Many new imaging agents.

Today's imaging agents are either easy to make but short-lived, or precise but hard to make without damaging the molecule. We remove that tradeoff.

Seeing what is hard to see today

Opens the way to precise imaging of cancers and other diseases that are difficult to detect with current agents.

Gentle on delicate molecules

Keeps the targeting molecule intact, so it still finds what it was designed to find.

Fits existing facilities

Designed to work with the equipment imaging centres already use.

Pipeline of new imaging agents, with lead programmes progressing toward first-in-human studies.
Work with us

Open to early adopters and collaborators.

If you work in cancer imaging, research or drug development, we'd like to hear from you.

Get in touch
Our team

The team behind the technology.

Sofia Otaru

Sofia Otaru, PhD

CEO

Expert in designing new imaging agents. Leads scientific and regulatory strategy.

Andreas Paulus

Andreas Paulus, PhD

CTO

Experience in clinical imaging agent production and the chemical industry. Leads technical development.

Khalil Elbadri

Khalil Elbadri

CBO

Background in drug delivery and translational research projects. Leads commercial strategy, partnerships and fundraising.

Advisors
Kim Bergström
Kim Bergström, PhDFormer Head of Cyclotron Unit, Helsinki University Hospital
Anu Airaksinen
Prof. Anu AiraksinenRadiopharmaceutical chemistry
Tiina Sikanen
Prof. Tiina SikanenMicrosystems design and development
Recognition

Research that has been recognised.

Researcher working at a radiochemistry hot cell in the lab
Photo: Anu Airaksinen
Award · 2024

Radioisotope Publication of the Year 2023

Finnish Society of Nuclear Medicine

Awarded to Sofia Otaru at the Finnish Isotope Days 2024 for the research behind our platform.

The paper describes a fast, efficient way to label delicate targeting molecules with an imaging marker. It was shown on several candidate imaging agents and evaluated in mice.

Source: Finnish Society of Nuclear Medicine newsletter 1/2024

Publications
  • Design and Preclinical Evaluation of Two Prostate-Specific Membrane Antigen-Targeting Trifluoroborate Derivatives Suitable for One-Step Radiofluorination

    Paulus A., Otaru S., Savela R., Imlimthan S., Auchynnikava T., Novotná D., Biti A., Sarparanta M., Liljenbäck H., Martinmäki T., Popkov A., Bergström K.A., Roivainen A., Airaksinen A.J. ACS Omega 2026, 11, 67448.

    Read the paper →
  • Radiolabelling of peptides with tetrazine ligation

    Otaru S., Martinmäki T., Kuurne I., Paulus A., Helariutta K., Sarparanta M., Airaksinen A.J. RSC Advances 2023, 13, 22606.

    Read the paper →
  • Development of [18F]AmBF3-tetrazine for radiolabeling of peptides

    Otaru S., Paulus A., Imlimthan S., Hirsso I., Virtanen H., Liljenbäck H., Auchynnikava T., Roivainen A., Helariutta K., Sarparanta M., Airaksinen A.J. Bioconjugate Chemistry 2022, 33, 1393–1404.

    Read the paper →
Contact

Get in touch.

Investors, partners and collaborators: write to us directly.